Clinical trial
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191048 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191048 |
|---|---|
| Title | Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD |
| Official title | Open-Label Treatment With Atomoxetine Hydrochloride in Child and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia |
| Intervention type | Drug |
| Interventions | Atomoxetine |
| Enrollment | 105 |
| Start date | Oct 1, 2003 |
| Completion | Mar 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: